Pediatric passive smoking exposure remains a largely unquantified cardiometabolic risk factor. The purpose of this study was to explore the consequences in adulthood of pediatric exposure to passive smoking, specifically via parental smoking exposure. The Cardiovascular Risk in Young Finns longitudinal study allowed the analysis of the presence of carotid plaque in adulthood given regular exposure to smoking by 1 or both parents. Exposure was measured by parental questionnaire. In a subset of participants, serum cotinine level, a biomarker of nicotine exposure, was also available from childhood. Our findings show that a significant association exists between exposure to 1 or both parents regularly smoking in childhood and the presence of carotid plaque in adulthood. Children exposed to 1 or both parents regularly smoking but with nondetectable child serum cotinine had significantly lower rates of carotid plaque in adulthood compared with children with 1 or both parents regularly smoking and subsequent high levels of serum cotinine in childhood. Although the risk was clearly lowest among those whose parents did not smoke, our findings suggest that for parents who continue smoking while parenting, maintaining good smoking hygiene can reduce adverse cardiovascular effects later in life for their offspring. Patient education on smoking cessation or harm reduction while caring for children should include advice on eliminating all potential instances of passive smoking exposure. See p 1239.
Myocardial Stiffness in Patients With Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin
Once heart failure with a preserved ejection fraction (HFpEF) has developed, subsequent morbidity and mortality rates are very high; the guideline-prescribed treatment of blood pressure and other comorbid conditions does not reduce these adverse outcomes. Randomized clinical trials in HFpEF of β-blockers, angiotension-converting enzyme inhibitors, angiotension II receptor blockers, aldosterone blockers, and phosphodiesterase type 5 inhibitors have failed to show improvement in morbidity or mortality. Therefore, there is a need for novel treatments that target the cellular, extracellular, and molecular mechanisms that cause the development of HFpEF. The current study identified 2 such mechanisms: changes in collagen content and titin phosphorylation, each of which could serve as potential therapeutic targets. Patients with HFpEF had increased total, collagen-dependent, and titin-dependent stiffness, increased insoluble collagen, increased titin phosphorylation on PEVK S11878(S26), and reduced phosphorylation on N2B S4185(S469). In addition, plasma biomarkers that reflect these changes in collagen, titin, and the profibrotic milieu were found to correlate with the presence and severity of HFpEF. Plasma tissue inhibitor of matrix metalloproteinase 1 and soluble ST-2 increased during the transition from hypertension to HFpEF. In addition, these biomarkers might be useful in monitoring treatment efficacy before changes in myocardial structure and function or clinical status are evident. Thus, the current studies suggest that the development of HFpEF depends on changes in collagen and titin homeostasis and the presence of a proinflammatory/profibrotic milieu. Each of these cellular, extracellular, and molecular mechanisms constitute important targets for the development of novel management strategies for HFpEF patients. See p 1247.
O-Linked β-N-Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension
Idiopathic pulmonary arterial hypertension (IPAH) is a progressive disease that leads to deterioration in cardiopulmonary function and premature death. Presently, IPAH is considered a vasculopathy, and metabolic dysregulation has emerged as a major area of research in the pathobiology of the disease. Several processes may be governed by the metabolic dysfunction present in IPAH, including enhanced pulmonary vascular cell proliferation, vascular remodeling, and vasoconstriction. Even though altered glucose uptake/metabolism has been characterized in IPAH, the nature of the primary abnormalities that trigger and perpetuate these characteristics remains unclear. Furthermore, the effectiveness of the current therapies is limited because they do not specifically target the pulmonary artery smooth muscle cell proliferation or vascular remodeling. In this report, using human IPAH and control patient lung tissues and pulmonary artery smooth muscle cells, we demonstrate that the increased pulmonary artery smooth muscle cell proliferation is directed by hexosamine biosynthetic pathway activation coupled with the enhancement of the O-linked β-N-acetylglucosamine transferase/O-linked β-N-acetylglucosamine axis. Our data point to a novel molecular mechanism whereby O-linked β-Nacetylglucosamine transferase directs the proteolytic activation of host cell factor-1, causing enhanced pulmonary artery smooth muscle cell proliferation, and worse disease outcomes in IPAH. These findings establish a novel regulatory role for the hexosamine biosynthetic pathway and O-linked β-Nacetylglucosamine transferase in IPAH, shed a new light on our understanding of the disease pathobiology, and provide opportunities to design novel therapeutic strategies for IPAH. Furthermore, these findings may have clinical implications for a wide array of diseases beyond IPAH, including cardiovascular disease, cancer, and diabetes mellitus. See p 1260.
Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting: Insights From the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial at the 5-Year Follow-Up
Optimal medical therapy (defined as the combination of at least 1 antiplatelet drug, statin, β-blocker, and Volume 131 ◼ Number 14 ◼ April 7, 2015
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angiotensin-converting enzyme inhibitor/angiotensin receptor blocker) is associated with a significant reduction in mortality and the composite end point of death/myocardial infarction/stroke in patients with complex coronary artery disease undergoing coronary revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery. All the components of optimal medical therapy are important for reducing adverse outcomes regardless of revascularization strategy. Optimal medical therapy should be considered for all patients with complex coronary artery disease treated with medical therapy, percutaneous coronary intervention, or coronary artery bypass graft surgery unless contraindicated. See p 1269. 
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